Affymax to Highlight Hematide[TM] Data at the American Society of Nephrology Renal Week 2009.Company Webcast on October 30(th) at 7:00 a.m. PT Features Physician Panel PALO ALTO, Calif. -- Affymax, Inc. (Nasdaq:AFFY) today announced multiple presentations at the American Society of Nephrology (ASN (1) (Autonomous System Number) A unique identifier of an autonomous system on the Internet. Of the 65 thousand ASNs available, more than 30 thousand have been assigned to ISPs and NSPs. ISPs usually have only one ASN, but NSPs may have more than one. ) Renal Week 2009 taking place October 27 through November 1 in San Diego. Affymax's drug, Hematide[TM], is currently in development with Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited (武田薬品工業株式会社 Limited for the treatment of anemia associated with chronic renal failure chronic renal failure Chronic kidney failure Nephrology A slow decline in renal function, which may be 2º to chronic HTN, DM, CHF, SLE, or sickle cell anemia and, if extreme, leads to ESRD, mandating kidney dialysis; an abrupt decline in renal function may be . Affymax and investigators will make multiple presentations highlighting Hematide preclinical and clinical data in various treatment settings. These include preliminary results of a Phase 2 trial in hemodialysis (HD) patients who are not on an erythropoiesis erythropoiesis /eryth·ro·poi·e·sis/ (-poi-e´sis) the formation of erythrocytes.erythropoiet´ic e·ryth·ro·poi·e·sis n. The formation or production of red blood cells. stimulating agent (ESA), and interim results from an ongoing Phase 2 study in patients with antibody-mediated pure red cell aplasia pure red cell aplasia Hematology A type of anemia caused by selective depletion of erythroid cells Pure red cell aplasia types Acute (Ab+PRCA). Details of Hematide presentations at ASN are as follows: *Note: All times are listed in Pacific Time [TABLE OMITTED] Company Webcast Affymax will host an investor webcast with Dr. Richard Lafayette, clinical chief of nephrology and associate professor of medicine at Stanford University Medical Center Stanford University Medical Center (Stanford Hospital & Clinics) is one of four hospitals affiliated with Stanford University and Stanford University School of Medicine, along with the Lucile Packard Children's Hospital, the Veteran's Administration Hospital in Palo Alto, and Santa , and Dr. Iain MacDougall, nephrology consultant at the Department of Renal Medicine, King's College Hospital King's College Hospital is a primary care facility in the London Borough of Lambeth, referred to locally and by staff simply as "King's" or abbreviated internally to "KCH". It serves an inner city population of 700,000 in the London boroughs of Lambeth, Southwark and Lewisham. . Dr. Lafayette will provide background on managing anemia in patients with chronic kidney disease Chronic kidney disease (CKD), also know as chronic renal disease, is a progressive loss of renal function over a period of months or years through five stages. Each stage is a progression through an abnormally low and progressively worse glomerular filtration rate, which is . Dr. MacDougall will discuss pure red cell aplasia (PRCA) a rare, serious and debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction autoimmune disorder, which can occur when the body produces neutralizing antibodies to the currently marketed recombinant human erythropoietins. The webcast will take place on Friday, October 30th from 7:00-8:00 a.m. PT, and may be accessed from the investors section of the company's website at www.affymax.com. A replay will also be available for 30 days following the presentation. About Hematide Hematide is a novel synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an erythropoiesis stimulating agent (ESA). Affymax and Takeda are collaborating on the development of Hematide and plan to co-commercialize the product once approved in the United States. The product, upon approval, will be commercialized in the European Union by Takeda. Phase 3 clinical trials are being conduced to investigate the potential for Hematide to treat anemia associated with chronic renal disease. About Anemia in Chronic Renal Failure (CRF) Anemia in CRF affects many individuals with Chronic Kidney Disease (CKD). According to the National Kidney Foundation Not to be confused with American Kidney Fund. The National Kidney Foundation, Inc. (NKF) is a major voluntary health organization in the United States. Its mission is to prevent kidney and urinary tract diseases, improve the health and well-being of individuals and , 26 million Americans - 1 in 9 U.S. adults - have CKD. Anemia develops in the early stages of CKD and worsens as patients progress towards total kidney failure and need a dialysis machine to eliminate waste and water from their blood. In severe or prolonged cases of anemia, the lack of oxygen in the blood can cause serious and sometimes fatal damage to the heart and other organs. Benefits of anemia correction in patients with CKD include decreased morbidity, hospitalization, and mortality.1 About Affymax, Inc. Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. For additional information, please visit www.affymax.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion